Doxorubicin News and Research

RSS
Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Bone marrow may be source of new egg-cell generation

Bone marrow may be source of new egg-cell generation

Designed drug for combined hormone and chemotherapy treatment

Designed drug for combined hormone and chemotherapy treatment

Chemo combo increases breast cancer survival

Chemo combo increases breast cancer survival

Breast cancer chemotherapy regimen associated with life-threatening complications

Breast cancer chemotherapy regimen associated with life-threatening complications

Doxorubicin-docetaxel combination is associated with an increased risk of severe and life-threatening complications

Doxorubicin-docetaxel combination is associated with an increased risk of severe and life-threatening complications

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Sildenafil prevents anti-cancer drug induced heart damage

Sildenafil prevents anti-cancer drug induced heart damage

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

Smart nanocarrier technology will cancer treatment

Smart nanocarrier technology will cancer treatment

Study focuses on best treatment for older women with receptor negative early breast cancer

Study focuses on best treatment for older women with receptor negative early breast cancer

Researchers step closer to cure for common childhood cancer

Researchers step closer to cure for common childhood cancer

Genetic predictions may bring “quantum leap” in breast cancer treatment success

Genetic predictions may bring “quantum leap” in breast cancer treatment success

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)

Dexrazoxane reduces heart damage caused by childhood leukemia treatment with doxorubicin (Adriamycin)